A5047288670- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- CAR-T cell therapy research
- Viral-associated cancers and disorders
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Platelet Disorders and Treatments
- CNS Lymphoma Diagnosis and Treatment
- Monoclonal and Polyclonal Antibodies Research
- Blood properties and coagulation
- Hematopoietic Stem Cell Transplantation
- Lung Cancer Treatments and Mutations
- Hemophilia Treatment and Research
- Acute Lymphoblastic Leukemia research
- Cutaneous lymphoproliferative disorders research
- Chemotherapy-induced cardiotoxicity and mitigation
- Acute Myeloid Leukemia Research
- Immune Cell Function and Interaction
- Neutropenia and Cancer Infections
- Biosimilars and Bioanalytical Methods
- COVID-19 Clinical Research Studies
- Multiple Myeloma Research and Treatments
- Chronic Myeloid Leukemia Treatments
- COVID-19 and healthcare impacts
- Blood groups and transfusion
- Sarcoma Diagnosis and Treatment
Clinica Universidad de Navarra
2022-2025
Centro de Investigación Biomédica en Red de Cáncer
2024-2025
Hospital Universitario La Paz
2015-2024
Navarre Institute of Health Research
2023-2024
Aims Community College
2023
Universidad Autónoma de Madrid
2005-2021
Universidad Nacional Agraria La Molina
2021
Central University Hospital of Asturias
2019
Ludwig-Maximilians-Universität München
2018
Ospedale Papa Giovanni XXIII
2018
Abstract Aim Cardiotoxicity (CTox) is a major side effect of cancer therapies, but uniform diagnostic criteria to guide clinical and research practices are lacking. Methods results We prospectively studied 865 patients, aged 54.7 ± 13.9; 16.3% men, scheduled for anticancer therapy related with moderate/high CTox risk. Four groups progressive myocardial damage/dysfunction were considered according current guidelines: normal, normal biomarkers (high-sensitivity troponin T N-terminal...
Abstract Background Patients with cancer have been shown to a higher risk of clinical severity and mortality compared non-cancer patients COVID-19. hematologic malignancies typically are known levels immunosuppression may develop more severe respiratory viral infections than solid tumors. Data on COVID-19 in limited. Here we characterize disease evaluate potential prognostic factors for mortality. Methods In this population-based registry study, collected de-identified data characteristics,...
Purpose The GALLIUM study ( ClinicalTrials.gov identifier: NCT01332968) showed that obinutuzumab (GA101; G) significantly prolonged progression-free survival (PFS) in previously untreated patients with follicular lymphoma relative to rituximab (R) when combined cyclophosphamide (C), doxorubicin, vincristine (V), and prednisone (P; CHOP); CVP; or bendamustine. This report focuses on the impact of chemotherapy backbone efficacy safety. Patients Methods A total 1,202 (grades 1 3a), advanced...
Background The role of re-treatment with rituximab in aggressive B-cell lymphomas still needs to be defined. This study evaluated the influence prior exposure on response rates and survival patients diffuse large lymphoma treated plus etoposide, cytarabine, cisplatinum methylprednisolone (R-ESHAP).Design Methods We retrospectively analyzed 163 relapsed or refractory who received R-ESHAP as salvage therapy a curative purpose. Patients were divided into two groups according whether had been...
In this work, we assessed the efficacy and safety of brentuximab vedotin (BV) plus ESHAP (BRESHAP) as second-line therapy for Relapsed/Refractory Hodgkin lymphoma (RRHL) to improve results before autologous stem-cell transplantation (ASCT).
Baseline cardiovascular toxicity risk stratification is critical in cardio-oncology. The Heart Failure Association (HFA) and International Cardio-Oncology Society (ICOS) score aims to assess this but lacks real-life validation. This study validates the HFA-ICOS for anthracycline-induced toxicity.
We report the results of reduced-intensity conditioning allogeneic stem cell transplantation (allo-RIC) in patients with advanced Hodgkin lymphoma (HL). Forty relapsed or refractory HL were homogeneously treated an RIC protocol (fludarabine 150 mg/m(2) intravenously plus melphalan 140 intravenously) and cyclosporin A methotrexate as graft-versus-host disease (GVHD) prophylaxis. Twenty-one (53%) had received >2 lines chemotherapy, 23 (58%) radiotherapy, 29 (73%) experienced treatment failure...
Summary The introduction of reduced‐intensity conditioning (RIC) has enabled the role allogeneic transplantation to be re‐evaluated in Hodgkin lymphoma (HL). While T‐cell depletion reduces graft‐versus‐host disease (GvHD), it potentially abrogates graft‐versus‐tumour activity and increases infective complications. We compared results 67 sibling donor transplantations following RIC multiply relapsed patients from two national phase II studies conditioned with fludarabine/melphalan. One used...
Currently, there are no consensus guidelines regarding the best therapeutic option for patients with extranodal marginal zone lymphomas of mucosa-associated lymphoid tissue (MALT) type.Patients systemically untreated or de novo MALT lymphoma received rituximab 375 mg/m(2) intravenously on Day 1 and fludarabine 25 Days through 5 (Days 1-3 in aged >70 years) every 4 weeks, to 6 cycles. After first cycle, oral could be given orally at 40 same schedule. 3 cycles, a workup was done. Patients who...
This phase II, single-arm, multicenter study examined the efficacy and safety of coltuximab ravtansine (an anti-CD19 antibody drug conjugate) in 61 patients with histologically documented (de novo or transformed) relapsed refractory diffuse large B-cell lymphoma who had previously received rituximab-containing immuno-chemotherapy. Patients a median 2.0 (range 0-9) prior treatment regimens for almost half (45.9%) bulky disease (≥1 lesion >5 cm) at trial entry. (55 mg/m2) 4 weekly biweekly...
Abstract Aims The actual usefulness of cardiovascular (CV) risk factor assessment in the prognostic evaluation cancer patients treated with cardiotoxic treatment remains largely unknown. Prospective multicentre study scheduled to receive anticancer therapy related moderate/high risk. Methods and results A total 1324 underwent follow-up a dedicated cardio-oncology clinic from April 2012 October 2017. Special care was given identification control CV factors. Clinical data, blood samples,...
Treatment resistance and toxicities remain a risk following chimeric antigen receptor (CAR) T-cell therapy. Herein, we report pharmacokinetics, pharmacodynamics, product apheresis attributes associated with outcomes among patients relapsed/refractory large B-cell lymphoma (LBCL) treated axicabtagene ciloleucel (axi-cel) in ZUMA-7. Axi-cel peak expansion clinical response toxicity, but not durability. In material final product, naive phenotype (CCR7+CD45RA+) expressing CD27 CD28 improved...
CAR T-cell therapy has emerged as a promising new immuno-oncology treatment that engages the patient's immune system to fight certain hematological malignancies, including diffuse large B-cell lymphoma (DLBCL). In European Union (EU), therapies have been approved for relapsed/refractory (R/R) DLBCL patients since 2018, but patient access is often still limited or delayed. This paper aimed at discussing challenges and possible solutions in largest four EU countries. The analysis relied on...
Several studies have focused on investigation of the optimal salvage regimen to induce maximum response before autologous stem cell transplantation (ASCT) in patients with relapsed or refractory Hodgkin's disease (HD). However, most these studies, follow‐up is relatively short. In present study, we report long‐term results 55 consecutive HD who received Mini‐BEAM [BCNU (carmustine), etoposide, cytarabine, melphalan] as therapy ASCT. Eleven were front‐line therapy, 17 partial responders, and...
Reactivation of hepatitis B infection is an increasing problem for patients with lymphoma, even in resolved infections, who were treated rituximab-based regimens. Our cases point out the need prolonged prophylaxis HBsAg-negative due to high risk developing fatal reactivation.